Drug Development/R&D
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
19th Annual Lecture: What Constitutes Credible Evidence of Effectiveness?
4 June 2013
Since 1993, OHE has hosted an annual lecture given by an eminent economist or clinician on an important current issue. In 2012, Professor Sir Michael Rawlins…
Realising the Value of Medical Research: Health and Economic Benefits
20 March 2013
OHE’s Jon Sussex is spoke today on the value of medical research at the 2013 BioWales conference, one of the UK’s largest life sciences conferences. Celebrating…
Reasons for Discontinuation of R&D Projects: Lead and Follow-on Indications
12 March 2013
The reasons for discontinuation of R&D projects in the biopharmaceutical industry are often a matter of conjecture. In a recent presentation to the 25th Annual EuroMeeting…
Overview of the OHE Study on the Cost of Drug Development Presented
29 January 2013
OHE’s Jorge Mestre-Ferrandiz reviewed the results of OHE’s recent study on the R&D cost of developing a new drug at a seminar at University College London.…
R&D Cost Drivers to be Explained by OHE Expert
18 January 2013
Jorge Mestre-Ferrandiz, lead author on OHE’s recent report on the cost of developing new drugs, will be discussing the important cost drivers at an upcoming UCL…
OHE Study on Pharmaceutical R&D Costs Released
3 December 2012
How much it costs to research and develop a successful new medicine has been an important policy issue at least since the 1960s. Cost estimates matter…
Join OHE in a Seminar to Discuss IP, Innovation and the Human Genome
19 October 2012
In this OHE lunchtime seminar, Prof Heidi Williams of MIT will present the results of a recent paper using newly-collected data on the sequencing of the…
Meeting the Challenges of Drug Development in 2022: Summary of OHE’s 50th Anniversary Conference
11 October 2012
To celebrate its 50th Anniversary, OHE held a conference this week, The Challenges and Economics of Drug Development in 2022, which explored the likely evolution of…
Advances in Oncology Modelling: Recent Results from POI Research
18 September 2012
OHE and the Pharmaceutical Oncology Initiative (POI) held a workshop to discuss and debate several key issues in oncology modelling. Participating were more than 50 experts…